The Exploration of Therapeutic Antivirals for Human Papillomavirus in the Last 40 Years: Bibliometric Research.

Zixiao Jiang, Liangrui Jin, Chengjun Wu, Zhenqing Li, Zhangrong Lou, Peng Qu

Abstract readEvidence Synthesis

In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zixiao JiangFaculty of Medicine, Dalian University of Technology, Dalian 116024, China.

Liangrui JinFaculty of Medicine, Dalian University of Technology, Dalian 116024, China.

Chengjun WuSchool of Health and Life Sciences, Qingdao Central Hospital, University of Health and Rehabilitation Science, Qingdao 266113, China.

Zhenqing LiOffice of Academic Affairs, Chengdu University of Technology, Chengdu 610095, China.ORCID 0000-0002-0637-4295

Zhangrong LouFaculty of Medicine, Dalian University of Technology, Dalian 116024, China.

Peng QuFaculty of Medicine, Dalian University of Technology, Dalian 116024, China.

Funding

Dalian University of Technology 2023-BSBA-057

6 · The paper itself

Abstract

Human papillomavirus (HPV) is a well-known carcinogenic DNA virus, responsible for about 4% of all cancer cases globally. Effective antiviral treatments for those who are already infected with HPV are still in their early stages, despite the fact that prophylactic vaccinations have shown impressive success in preventing new infections. Effective treatments for HPV-related malignancies are also hampered by the fact that current articles address a wide spectrum of pathways but lack thorough systematic studies. In this work, we use bibliometric techniques to examine research trends and innovative approaches in the development of HPV antivirals over the last 40 years. Our results are intended to offer insightful information and direct future research into effective antiviral treatments for HPV-induced cancers.

Indexed as

Antiviral AgentsHuman Papillomavirus VirusesPapillomavirus InfectionsBibliometricsHumansAntiviral Agentsantiviralbibliometricshuman papillomavirus

Identifiers

PMID41901718

DOI10.3390/pathogens15030265

PMCPMC13029675

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.